On April 20, 2026, Eli Lilly and Company (NYSE: LLY) announced that it has entered into a definitive agreement to acquire Kelonia Therapeutics Inc., a clinical-stage biotechnology company pioneering in in vivo gene delivery in a deal valued at up to $7Bn.

The proposed transaction would expand Lilly’s presence in the genetic medicine space, adding Kelonia’s proprietary lentiviral vector (LVV) platform and clinical-stage cell therapy pipeline to Lilly’s existing portfolio of metabolic, oncology and immunology assets. If completed, the combination is expected to meaningfully strengthen Lilly’s position in next-generation therapeutics, particularly in the treatment of hematologic diseases and solid tumors where durable, single-administration therapies may offer significant clinical and commercial advantages.

Strategic Rationale

Eli Lilly is an Indianapolis-based global pharmaceutical company with a research-driven portfolio spanning oncology, diabetes, obesity, immunology and neuroscience. The acquisition of Kelonia represents the company’s most substantial commitment to date in cell therapy and reinforces a deliberate strategy of building in vivo capability through acquisition. It follows Lilly’s purchase of Orna Therapeutics, an in vivo cell therapy developer, earlier in 2026 – a sequence that signals a coordinated effort to assemble platform technologies rather than single assets.

For Lilly, the strategic appeal of in vivo CAR-T lies in its potential to address the structural limitations of conventional autologous therapies. Established CAR-T treatments require extracting a patient’s T-cells, engineering them in a specialized facility and reinfusing them – a process that is costly, time-intensive and accessible only to a fraction of eligible patients. Kelonia’s approach generates CAR-T cells inside the body through a single intravenous administration, removing the external manufacturing step entirely. If validated at scale, the platform could broaden the addressable patient population well beyond the reach of current cell therapies and extend into a wider range of cancers and other serious diseases.

Kelonia Therapeutics is a Boston-based, clinical-stage biotechnology company focused on in vivo gene delivery for cell therapy applications. The company’s decision to pursue a sale reflects the strategic calculus facing a clinical-stage developer with a differentiated platform but a long and capital-intensive path to commercialization. Advancing an in vivo cell therapy program through late-stage trials, regulatory review and eventual manufacturing scale requires resources and infrastructure that an independent biotech company of Kelonia’s size would otherwise find difficult to assemble on a competitive timeline.

The combination with Lilly provides Kelonia’s platform with development capital, manufacturing capability and global commercial reach that materially de-risk its path forward. The transaction structure also permits Kelonia’s shareholders to retain meaningful exposure to the platform’s success: the future contingent payments that are part of the transaction consideration preserve a substantial portion of potential value for realization as the technology achieves clinical, regulatory and commercial milestones. For a company whose principal asset is a platform still in early clinical validation, the combination of upfront liquidity and future milestone participation offers an attractive balance between certainty and continued upside.

Transaction Overview

Lilly will pay $3.25Bn upfront, while the remaining payments of ~$3.75Bn are contingent upon clinical, regulatory and commercial milestones. The transaction is expected to close in the second half of 2026.

The deal fits into Lilly’s broader strategy of acquiring innovative platform technologies earlier in their development lifecycle. In recent years, Lilly has pursued a series of acquisitions and partnerships designed to supplement its internal research capabilities with externally developed science, particularly in areas where novel mechanisms of action could differentiate its portfolio.

Upon completion of the acquisition, Lilly expects to integrate Kelonia’s research operations and advance its lead programs through ongoing and planned clinical trials. Kelonia’s most advanced asset is currently in Phase 1/2 development for a rare hematologic condition, with additional preclinical programs targeting oncology indications. The combined organization would likely benefit from Lilly’s resources in clinical operations, manufacturing scale-up and regulatory affairs as Kelonia’s programs progress toward potential pivotal studies.

Financial Terms and Valuation Considerations

The transaction structure – of immediate and contingent cash, with no equity component – reflects Lilly’s strong balance sheet and its stated preference for transactions that provide certainty of value to target shareholders while avoiding equity dilution.

From a valuation standpoint, the acquisition price of $7Bn represents a premium to Kelonia’s most recent private valuation, reflecting the strategic premium Lilly appears willing to pay for proprietary platform technologies with broad potential applicability. While Kelonia does not yet generate commercial revenue, the transaction price likely reflects the anticipated value of its pipeline, the differentiation of its LVV delivery technology and the potential market opportunity across multiple therapeutic areas. The acquisition multiple is consistent with recent precedent transactions in the cell and gene therapy space, where platform acquisitions have generally commanded premium valuations relative to near-term revenue or earnings metrics.

Lilly has indicated that the transaction is expected to be dilutive to earnings per share in the near term, reflecting the upfront cost of the acquisition and anticipated investment in advancing Kelonia’s clinical programs. However, Lilly’s management has suggested that the long-term value creation potential associated with successful development of Kelonia’s assets is expected to outweigh the near-term financial impact. The transaction has been unanimously approved by both companies’ boards and remains subject to customary closing conditions, including regulatory review.

Sector Context

Large pharmaceutical companies have moved to secure differentiated delivery platforms through acquisition, recognizing that the next phase of competition in cell therapy may be defined less by individual targets than by the technologies that enable scalable, accessible administration.

About DelMorgan & Co. (www.delmorganco.com)

With over $300 billion of successful transactions in over 80 countries, DelMorgan‘s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe. DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.

Learn more about DelMorgan’s Capabilities, Transactions, and why DelMorgan is ranked as the #1 Investment Bank in Los Angeles and #2 in California by Axial.